Spanish biotech acquires Gene Predictis SA

Based in Ecublen (VD), Gene Predictis SA develops and commercializes innovative, clinically relevant diagnostic tools based on genetics. The solution allows for improving drug treatment efficacy and reducing harmful side effects, nutrition and lifestyle and preventing disease development. In 15 years of its existence, the company has performed more than 50,000 analyses, including analysis for Covid-19.

Gene Predictis has entered a new phase, thanks to its exit to NIMGenetics, a science-led genetic diagnostic company that develops and distributes genetic diagnostic tests, reagents and associated software. MIN has a presence in Spain, Portugal, Brazil, and Mexico, serving customers globally. In addition to boosting its expansion in Europe and reinforcing its presence outside of Spain, the acquisition of Gene Predictis allows NIM to broaden its portfolio by adding new verticals such as pharmacogenetics, predictive genetics, microbiology and infectious diseases. Similarly, the takeover allows Gene Predictis to accelerate its growth in the international market.

The synergies and customer growth for both companies will place NIM at the forefront of the genetic diagnostics market in Europe. As Enrique Samper, co-founder and CEO of NIM stated: “This acquisition will boost our expansion in Europe and usher in a new phase of development marked by future strategic alliances”.

Gene Predictis CEO, Goranka Tanackovic, describes the integration into the group as “a great opportunity to expand our activity internationally and to focus on our main areas of expertise”. Anne-Laure Meynier, Investment Director at Apposite Capital, added: “We are delighted that NIM has completed this acquisition. This demonstrates that NIM is an attractive platform for market consolidation, adding partner firms – aligned with our high-quality products and service delivery – to the group, supporting rapid growth of local provision.”

(Press release/RAN)